DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer.
Qi ZouXiaolin WangDonglin RenBang HuGuannan TangYu ZhangMeijin HuangRish K PaiDaniel D BuchananAung Ko WinPolly A NewcombWilliam M GradyHuichuan YuYanxin LuoPublished in: Journal for immunotherapy of cancer (2022)
This study developed a quantitative DNA methylation-based signature that was reliable to evaluate CD8+ TILs and prognosis in CRC. This approach has the potential to be a tool for investigations on CD8+ TILs and a biomarker for therapeutic approaches, including immunotherapy.